RecruitingNot ApplicableNCT06819449

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial


Sponsor

South Valley University

Enrollment

50 participants

Start Date

Dec 20, 2024

Study Type

INTERVENTIONAL

Summary

Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.


Eligibility

Min Age: 5 YearsMax Age: 60 Years

Inclusion Criteria1

  • Patients of both sexes with positive slit skin smear for m.leprae .

Exclusion Criteria4

  • Contraindications to Multi drug therapy :
  • Patients with hypersensitivity to sulfa .
  • Patients with hypersensitivity to clofazimine or rifampcin.
  • pregnant or lactating women.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDapsone

To evaluate the effect of the multi drug therapy in leprotic patients and their side effects and to assess the role of Rab 32 gene in leprosy prognosis and to know its association with the multi drug therapy.


Locations(1)

Qina University hospital, South Valley University Hospital

Qina, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06819449